Funds will help the companies create a platform for the manufacturing and characterization of AAV-based gene therapy vectors.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jason C. Foster, CEO of Ori Biotech, ...

Apriori Bio has become the latest Flagship Pioneering-backed biotech to shed staff, cutting 15 workers to leave 21 still ...

The IIT Roorkee study on Efavirenz offers a new avenue for Chikungunya treatment, bringing optimism to patients and doctors ...

The “slow but consistent increase” in global temperatures is enabling climate-sensitive disease vectors, such as mosquitoes ...

Facility in Gliwice, Poland to boost biopharma manufacturers' efficiency and speed to market of therapies ...

Sesame AI has publicly released the underlying technology powering its wildly popular Maya voice assistant. The company ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

According to the World Health Organization, vector-borne diseases cause more than 700,000 deaths annually. Researchers sound ...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal ...

The recent USDA report about four black rats testing positive for bird flu in Riverside County, Calif., has raised questions ...

Federal authorities have issued an advisory warning people of Medusa ransomware that has breached the data of more than 300 ...